Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Form 4 filing overview: On 07/02/2025, Incyte Corp. (INCY) Principal Accounting Officer Tray Thomas satisfied tax-withholding obligations related to previously granted restricted stock units (RSUs).
- Transaction code F denotes shares withheld by the issuer for taxes—not an open-market sale.
- Shares withheld: 897 common shares at an implied price of $68.17.
- Post-transaction holdings: 21,106 common shares, of which 13,456 are unvested RSUs.
No derivative securities were exercised or disposed of. The filing represents an administrative, non-discretionary transaction and does not signal a change in the executive’s investment thesis or company fundamentals.